Correction:Cilostazol and isosorbide mononitrate for the prevention of progression of:baseline data and statistical analysis plan for the Lacunar Intervention Trial-2(LACI-2)(ISRCTN14911850)  

出　　处：《Stroke & Vascular Neurology》2023年第2期I0001-I0001,共1页卒中与血管神经病学（英文）

摘　　要：Bath PM,Mhlanga I,Woodhouse LJ,et al.Cilostazol and isosorbide mononitrate for the prevention of progression of:baseline data and statistical analysis plan for the Lacunar Intervention Trial-2(LACI-2)(ISRCTN14911850).Stroke Vasc Neurol 2022;svn-2022-001816.doi:10.1136/svn-2022-001816 The article was erroneously published without the full title as Cilostazol and isosorbide mononitrate for the prevention of progression of:baseline data and statistical analysis plan for the Lacunar Intervention Trial-2(LACI-2)(ISRCTN14911850).This has been amended to Cilostazol and isosorbide mononitrate for the prevention of progression of cerebral small vessel disease:baseline data and statistical analysis plan for the Lacunar Intervention Trial-2(LACI-2)(ISRCTN14911850).Also,there are LACI 2 Investigators added along with author names in title page.The details of the investigators are added as a supplemental material in the article.

关 键 词：nitrate DETAILS PREVENTION 

分 类 号：R741-5[医药卫生—神经病学与精神病学] G23[医药卫生—临床医学]